Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Isopropyl Acetate | HCID 7915 | — |
| Reactant | Erlotinib | HCID 176870 | — |
| Reactant | Hydrogen chloride-ethyl acetate | HCID 21866389 | — |
| Product | Erlotinib Hydrochloride | HCID 176871 | — |
Reaction Steps
Erlotinib free base (10 gm) is added to isopropyl acetate (400 ml) under stirring at 25-30° C., the contents are heated to 60° C. and then stirred at 60-65° C. to form a clear solution. To the solution slowly added 7% ethyl acetate HCl (40 ml) at 60-65° C. and stirred for 2 hours at 60-65° C. The resulting mass is slowly cooled to 25-30° C. and then stirred for 1 hour. Filtered the mass, washed with the mixture of isopropyl acetate (40 ml) and ethyl acetate (4 ml) and then dried at 50-55° C. to give 9.9 gm of erlotinib hydrochloride crystalline polymorph form A having polymorph form B undetected [HPLC Purity: 99.89%; to Moisture Content: 0.15%; Mean particle size (D50): 5.48 μm and 90 volume-% of the particles (D90): 18.96 μm].
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08669265B2 |
|---|
| Source dataset | uspto-grants-2014_03 |
|---|
| ORD ID | ord-906be36e24764c4798a7333c2986f66a |
|---|
| Source note | uspto-grants-2014_03 |
|---|